A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation

  • Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V. Karg, Peter Bramlage, Roland E. Schmieder
  • Cardiovascular Diabetology, February 2017, Springer Science + Business Media
  • DOI: 10.1186/s12933-017-0510-1

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1186/s12933-017-0510-1

The following have contributed to this page: Peter Bramlage